Related Experiment Video
Updated: Jul 13, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
In silico study of some plant compounds as potential anticancer agents targeting MALT1 allosteric domain
Mohammed M Alshehri1, Mohammed Kanan Alshammari2, Mohammed Khalid Alghazwni3
1Pharmaceutical Care Department, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
Abstract:
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is the only human paracaspase, that serves as an adaptor protein and controls substantial genes expressed in the activation, proliferation of lymphocyte, and immune reactions by triggering the IKK/NF-kB signaling pathway. However, unusual MALT1-mediated NF-kB signaling pathway has been identified in multiple diseases like cancer, therefore making MALT1 a promising therapeutic target. There are scanty numbers of MALT1 inhibitors, thus the need to discover more compounds with less or no toxicity issue, that are cheap and pharmacologically efficient is of pertinence. Hence, our present study was to identify phyto-small molecules that could bind the allosteric interface of MALT1 using in silico methods. Total of 34 plant molecules were selected and screened for druglikeness, after which they were docked via Maestro 11.1 against the allosteric site of MALT1. The molecule with a binding score (kcal/mol) better than the control drug was subjected to molecular dynamics (MD) simulations of 100 ns via Desmond, free energy perturbations, principal component and Pearson correlation analyses. Our findings from this computational study presents cyanidin (-8.822 kcal/mol) as better binder to the allosteric site of MALT1 based on the molecular docking and pharmacokinetic profiling than thioridazine. Similarly, cyanidin-MALT1 complex showed significant stability and exhibiting contacts with critical amino acid residues in the site of interest than thioridazine-MALT1 complex. Hence, cyanidin is a potential allosteric inhibitor of MALT1. However, an urgent need for in vitro and in vivo validations is required to ascertain the efficacy of cyanidin in the fight against cancer and other MALT1-related diseases.
Insights
Cyanidin shows potential as a MALT1 inhibitor, identified through computational screening of plant molecules. This discovery offers a promising avenue for developing new cancer therapies targeting the MALT1 signaling pathway.
Area of Science:
- Biochemistry
- Computational Chemistry
- Pharmacology
Background:
- Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a key adaptor protein regulating lymphocyte activation and immune responses via the IKK/NF-kB pathway.
- Dysregulated MALT1 activity is implicated in various diseases, including cancer, making it a significant therapeutic target.
- A limited number of MALT1 inhibitors exist, necessitating the discovery of novel, safe, and effective compounds.
Purpose of the Study:
- To identify potential phyto-small molecules that can bind to the allosteric interface of MALT1 using in silico methods.
- To screen and evaluate plant-derived compounds as potential MALT1 inhibitors.
- To assess the binding affinity and stability of identified compounds with MALT1.
Main Methods:
- In silico screening of 34 plant molecules for druglikeness.
- Molecular docking of selected compounds against the MALT1 allosteric site using Maestro 11.1.
- Molecular dynamics (MD) simulations (100 ns via Desmond), free energy perturbations, and principal component analyses for promising candidates.
Main Results:
- Cyanidin demonstrated superior binding affinity (-8.822 kcal/mol) to the MALT1 allosteric site compared to the control drug thioridazine.
- The cyanidin-MALT1 complex exhibited significant stability and crucial interactions with key amino acid residues.
- Pharmacokinetic profiling supported cyanidin's potential as a MALT1 inhibitor.
Conclusions:
- Cyanidin is identified as a potential allosteric inhibitor of MALT1 based on computational analyses.
- The study highlights cyanidin as a promising lead compound for further investigation.
- In vitro and in vivo validation is crucial to confirm cyanidin's efficacy against MALT1-related diseases, particularly cancer.

